Asia-Pacific Surgical Site Infection Control Market Growth Prospects 2024-2032

Asia-Pacific Surgical Site Infection Control Market Growth Prospects 2024-2032

According to Triton’s research report, the Asia-Pacific surgical site infection control market is expected to advance at a CAGR of 6.14% over the forecast years 2024-2032.

The surgical site infection control market in the Asia-Pacific region is witnessing significant growth, driven by increasing healthcare expenditures and rising awareness of infection control practices. The World Health Organization (WHO) has emphasized the critical need for improved infection prevention and control (IPC), noting that surgical site infections are among the most common healthcare-associated infections, with an estimated 11% of surgical patients affected in low- and middle-income countries. This has prompted healthcare facilities to adopt stricter infection control protocols, further spurred by government initiatives aimed at reducing healthcare-associated infections.

The countries evaluated in this region comprise China, ASEAN Countries, Japan, India, South Korea, Australia & New Zealand, and Rest of Asia-Pacific.

China spearheads the regional market, attaining around $325.1 million in 2023

In China, surgical site infections are notably prevalent, with several studies conducted to determine their incidence. One comprehensive study reported an overall SSI rate of around 4.7% across various departments, including internal medicine, oncology, neurology, and obstetrics.

The government has been proactive in addressing the issue of surgical site infections through stringent regulatory frameworks and national guidelines. For instance, the National Health Commission of China has implemented several infection prevention and control (IPC) programs aimed at reducing the incidence of SSIs. These programs are part of broader initiatives to enhance patient safety and improve the quality of healthcare services.

These developments align with the Health China 2030 initiative, which emphasizes the need for improved health outcomes through better healthcare services and infection control.

Market Forecast for India

In India, public hospitals face inadequate administrative and financial support, hindering comprehensive infection control programs. This leads to extremely low nurse-to-patient ratios, particularly in intensive care units, where high HAI rates and overcrowding are common. Several factors, including an aging population, contaminated wounds, prolonged surgeries, the use of drains, and extended hospital stays, contribute to a higher incidence of surgical site infections (SSI). These growing challenges, coupled with an increase in surgical procedures and the expanding elderly population, are expected to drive demand for effective surgical site infection management across India.

The market is segmented based on industry vertical, procedure, type of infection, and product. The industry vertical segment includes ambulatory surgical centers and hospitals.

Ambulatory care refers to medical services provided in facilities where patients do not stay overnight, such as outpatient clinics, physicians’ offices, urgent care centers, and rehabilitation centers. Healthcare-associated infections remain a common complication after ambulatory surgeries. However, most of these infections are preventable due to stringent regulations that ensure ambulatory surgical centers (ASCs) maintain the same high safety standards as hospitals. Advances in technology, anesthesia, and minimally invasive procedures have made surgeries at ASCs safer.

Contender Analysis in the Surgical Site Infection Control Market:

Johnson & Johnson, based in the United States, is involved in the research, development, manufacturing, and marketing of personal care products, pharmaceuticals, and surgical equipment. The company operates through three main segments: medical devices, pharmaceuticals, and consumer health. The medical devices segment supplies products to wholesalers, retailers, and hospitals, primarily used by healthcare professionals in various settings. These products address needs in orthopedics, cancer treatment, cardiovascular care, etc. Founded in 1886, Johnson & Johnson serves clients across varied regions, including Asia-Pacific.

In May 2024, Ethicon, a Johnson & Johnson MedTech company, launched the ECHELON LINEAR™ Cutter. This device integrates 3D-Stapling Technology and Gripping Surface Technology (GST) that reduces staple line leaks by 47%, reducing surgical risks.

Other notable companies offering solutions in the market include Sotera Health LLC, Steris Corporation, Stryker Corporation, and Kimberly-Clark Corporation.

ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET 2024-2032.pdf